<html>
<head>PUBMED IDs for c-ABL</head>
<body bgcolor='#C5F0F2'><h1>c-ABL</h1><a href='https://pubmed.ncbi.nlm.nih.gov/2005881/'>BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.</a> April 1  1991<br><a href='https://pubmed.ncbi.nlm.nih.gov/1900918/'>Characterization of the BCR promoter in Philadelphia chromosome-positive and -negative cell lines.</a> April 1  1991<br><a href='https://pubmed.ncbi.nlm.nih.gov/7682703/'>En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase.</a> April 15  1993<br><a href='https://pubmed.ncbi.nlm.nih.gov/8414522/'>Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity.</a> November 1  1993<br><a href='https://pubmed.ncbi.nlm.nih.gov/8649822/'>Identification of a human LIM-Hox gene, hLH-2, aberrantly expressed in chronic myelogenous leukaemia and located on 9q33-34.1.</a> March 21  1996<br><a href='https://pubmed.ncbi.nlm.nih.gov/9174663/'>Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL.</a> March 1  1997<br><a href='https://pubmed.ncbi.nlm.nih.gov/9096220/'>Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras.</a> March 28  1997<br><a href='https://pubmed.ncbi.nlm.nih.gov/9144171/'>Protein binding and signaling properties of RIN1 suggest a unique effector function.</a> May 13  1997<br><a href='https://pubmed.ncbi.nlm.nih.gov/9195915/'>Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells.</a> June 27  1997<br><a href='https://pubmed.ncbi.nlm.nih.gov/9312168/'>A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo.</a> October 6  1997<br><a href='https://pubmed.ncbi.nlm.nih.gov/9593259/'>Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells.</a> May 21  1998<br><a href='https://pubmed.ncbi.nlm.nih.gov/9676840/'>Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).</a> July 24  1998<br><a href='https://pubmed.ncbi.nlm.nih.gov/9808578/'>The C-terminus of c-ABL is required for proliferation and viability signaling in a c-ABL/erythropoietin receptor fusion protein.</a> November 10  1998<br><a href='https://pubmed.ncbi.nlm.nih.gov/9879825/'>Chronic myelogenous leukemia: molecular and cellular aspects.</a> January 8  1999<br><a href='https://pubmed.ncbi.nlm.nih.gov/10339507/'>Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells.</a> May 26  1999<br><a href='https://pubmed.ncbi.nlm.nih.gov/10454801/'>Prognostic significance of c-ABL methylation in chronic myelogenous leukemia: still an open question.</a> August 24  1999<br><a href='https://pubmed.ncbi.nlm.nih.gov/10565030/'>Inhibition of c-ABL expression in hematopoietic progenitor cells using antisense oligodeoxynucleotides.</a> November 24  1999<br><a href='https://pubmed.ncbi.nlm.nih.gov/11121477/'>A novel four zinc-finger protein targeted against p190(BcrAbl) fusion oncogene cDNA: utilisation of zinc-finger recognition codes.</a> January 11  2000<br><a href='https://pubmed.ncbi.nlm.nih.gov/10648416/'>A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia.</a> January 29  2000<br><a href='https://pubmed.ncbi.nlm.nih.gov/10739668/'>A comparison of the activity, sequence specificity, and CRM1-dependence of different nuclear export signals.</a> March 31  2000<br><a href='https://pubmed.ncbi.nlm.nih.gov/10794714/'>Exon-skipping in BCR/ABL is induced by ABL exon 2.</a> May 5  2000<br><a href='https://pubmed.ncbi.nlm.nih.gov/11337505/'>Nuclear export of human beta-catenin can occur independent of CRM1 and the adenomatous polyposis coli tumor suppressor.</a> May 5  2001<br><a href='https://pubmed.ncbi.nlm.nih.gov/11345193/'>Mechanisms of transformation by the BCR/ABL oncogene.</a> May 10  2001<br><a href='https://pubmed.ncbi.nlm.nih.gov/11587359/'>Phosphatidyl inositol signaling by BCR/ABL: opportunities for drug development.</a> October 6  2001<br><a href='https://pubmed.ncbi.nlm.nih.gov/12573349/'>Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.</a> February 8  2003<br><a href='https://pubmed.ncbi.nlm.nih.gov/12679488/'>The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.</a> April 8  2003<br><a href='https://pubmed.ncbi.nlm.nih.gov/12908554/'>Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.</a> August 12  2003<br><a href='https://pubmed.ncbi.nlm.nih.gov/14732695/'>A role for p300/CREB binding protein genes in promoting cancer progression in colon cancer cell lines with microsatellite instability.</a> January 21  2004<br><a href='https://pubmed.ncbi.nlm.nih.gov/14987801/'>ABL-fusion oncoproteins activate multi-pathway of DNA repair: role in drug resistance?</a> February 28  2004<br><a href='https://pubmed.ncbi.nlm.nih.gov/15121862/'>Tumor necrosis factor alpha-induced apoptosis requires p73 and c-ABL activation downstream of RB degradation.</a> May 4  2004<br><a href='https://pubmed.ncbi.nlm.nih.gov/15492510/'>BCR/ABL recruits p53 tumor suppressor protein to induce drug resistance.</a> October 20  2004<br><a href='https://pubmed.ncbi.nlm.nih.gov/16983347/'>Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.</a> September 20  2006<br><a href='https://pubmed.ncbi.nlm.nih.gov/17196995/'>aCGH local copy number aberrations associated with overall copy number genomic instability in colorectal cancer: coordinate involvement of the regions including BCR and ABL.</a> January 2  2007<br><a href='https://pubmed.ncbi.nlm.nih.gov/20425353/'>Genomic instability: The cause and effect of BCR/ABL tyrosine kinase.</a> August 7  2007<br><a href='https://pubmed.ncbi.nlm.nih.gov/20000211/'>Breast cancer and the family tree. An issue for all practice settings.</a> January 7  2007<br><a href='https://pubmed.ncbi.nlm.nih.gov/19453417/'>Oligonucleotide microchip for subtyping of influenza A virus.</a> June 10  2007<br><a href='https://pubmed.ncbi.nlm.nih.gov/17471591/'>Switching on transgene expression by correcting aberrant splicing using multi-targeting steric-blocking oligonucleotides.</a> May 2  2007<br><a href='https://pubmed.ncbi.nlm.nih.gov/17471590/'>Delivery and long-term expression of a 135 kb LDLR genomic DNA locus in vivo by hydrodynamic tail vein injection.</a> May 2  2007<br><a href='https://pubmed.ncbi.nlm.nih.gov/17471589/'>In vivo expression of human ATP:cob(I)alamin adenosyltransferase (ATR) using recombinant adeno-associated virus (rAAV) serotypes 2 and 8.</a> May 2  2007<br><a href='https://pubmed.ncbi.nlm.nih.gov/17471588/'>Gene transfer of human TCR in primary murine T cells is improved by pseudo-typing with amphotropic and ecotropic envelopes.</a> May 2  2007<br><a href='https://pubmed.ncbi.nlm.nih.gov/17471587/'>Comparison of cDNA and genomic forms of tyrosine hydroxylase gene therapy of the brain with Trojan horse liposomes.</a> May 2  2007<br><a href='https://pubmed.ncbi.nlm.nih.gov/17471586/'>Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer.</a> May 2  2007<br><a href='https://pubmed.ncbi.nlm.nih.gov/17471573/'>HPV related VIN: highly proliferative and diminished responsiveness to extracellular signals.</a> May 2  2007<br><a href='https://pubmed.ncbi.nlm.nih.gov/17486070/'>Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1.</a> May 9  2007<br><a href='https://pubmed.ncbi.nlm.nih.gov/17504122/'>The kinase inhibitor imatinib--an immunosuppressive drug?</a> May 17  2007<br><a href='https://pubmed.ncbi.nlm.nih.gov/17570524/'>A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients.</a> June 16  2007<br><a href='https://pubmed.ncbi.nlm.nih.gov/18391983/'>Activated c-Abl tyrosine kinase in malignant solid tumors.</a> April 9  2008<br><a href='https://pubmed.ncbi.nlm.nih.gov/18848355/'>Supplemental results of the detection of splicing variant with c-ABL exon 7 deletion by direct sequencing Comment on &quot;A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients&quot; by Curvo et al. [Leuk. Res.].</a> October 14  2008<br><a href='https://pubmed.ncbi.nlm.nih.gov/19643477/'>mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein.</a> April 24  2009<br><a href='https://pubmed.ncbi.nlm.nih.gov/20234815/'>Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer.</a> June 25  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/21498698/'>Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016).</a> June 22  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/21536647/'>Forced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatment.</a> August 24  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/21804533/'>Tyrosine phosphorylation enhances RAD52-mediated annealing by modulating its DNA binding.</a> November 4  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/21816343/'>The Ewing sarcoma protein regulates DNA damage-induced alternative splicing.</a> October 11  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/21872826/'>Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors.</a> October 22  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/23047478/'>B-lineage transcription factors and cooperating gene lesions required for leukemia development.</a> May 1  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/23117882/'>ABL regulation by AXL promotes cisplatin resistance in esophageal cancer.</a> February 28  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/24960160/'>A phosphotyrosine switch determines the antitumor activity of ERÎ².</a> February 19  2014<br></body></html>
